ATAI Live signals | Maximize Profits with Getagraph.com

SELL 102003 min ago

@ $1.778

Issued: 14 Feb 2024 @ 09:30

Return: 5.16%

Previous signal: Feb 12 - 14:27

Previous signal: Buy

Return: -3.36 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	834 410
Average Volume	1.63M
Market Cap	310.47M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.200 ) 2024-05-09
Last Dividend	$6.00 ( 2018-08-27 )
Next Dividend	$0 ( N/A )
P/E	-7.48
ATR14	$0.00400 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Apeiron Investment Group Ltd.	Buy	147 950	Convertible Notes
2024-04-15	Apeiron Investment Group Ltd.	Sell	147 950	Convertible Notes
2024-04-02	Johnson Anne Nagengast	Sell	27 410	Common Shares
2024-04-02	Rao Srinivas	Sell	61 640	Common Shares
2024-04-02	Kirpekar Sahil	Sell	35 801	Common Shares

INSIDER POWER
56.51
Last 90 transactions
Buy: 18 737 833 \| Sell: 13 770 797

Volume Correlation

Long: 0.12 (neutral)

Short: -0.68 (moderate negative)

Signal:(41.314) Neutral

ATA Inc. Correlation

10 Most Positive Correlations
LLNW	0.94
PAVM	0.928
SVOK	0.916
IMCC	0.913
NVTSW	0.913
SWAV	0.912
QTEK	0.912
RDHL	0.911
QAT	0.91
NKTX	0.91

10 Most Negative Correlations
ITMR	-0.949
AVEO	-0.939
GAINM	-0.933
XOMAO	-0.931
DVCR	-0.925
ALXN	-0.923
PPD	-0.923
GLLI	-0.923
MLCO	-0.923
ACAB	-0.922

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ATA Inc. Correlation - Currency/Commodity

-0.77
( moderate negative )

-0.78
( moderate negative )

0.00
( neutral )

0.58
( weak )

-0.10
( neutral )

ATA Inc. Financials

Annual	2023
Revenue:	$314 000
Gross Profit:	$-5 000.00 (-1.59 %)
EPS:	$-0.250

Q4	2023
Revenue:	$18 000.00
Gross Profit:	$-83 000.00 (-461.11 %)
EPS:	$-0.120

Q3	2023
Revenue:	$87 000.00
Gross Profit:	$13 000.00 (14.94 %)
EPS:	$0.280

Q2	2023
Revenue:	$172 000
Gross Profit:	$-23 000.00 (-13.37 %)
EPS:	$-0.210

Financial Reports:

No articles found.

ATA Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

ATA Inc. Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.430	2011-06-28
Last Dividend	$6.00	2018-08-27
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$7.36	--
Avg. Dividend % Per Year	0.00%	--
Score	0.25	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-09-15)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.25

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-128.70	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.138	1.200	-4.59	-5.51	[0 - 0.3]
returnOnEquityTTM	-0.920	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.22	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.78	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.24	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0528	-1.500	9.12	-10.00	[0 - 0.6]
interestCoverageTTM	-46.97	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.524	2.00	-0.175	-0.349	[0 - 30]
freeCashFlowPerShareTTM	-0.528	2.00	-0.264	-0.528	[0 - 20]
debtEquityRatioTTM	0.0637	-1.500	9.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	-0.710	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-397.42	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-5.38	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00107	0.800	-3.33	-2.66	[0.5 - 2]
Total Score				-2.40

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-7.35	1.000	-0.843	0	[1 - 100]
returnOnEquityTTM	-0.920	2.50	-7.29	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.528	2.00	-0.176	-0.528	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.524	2.00	-0.175	-0.349	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0771	1.500	-3.85	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-265.15	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.73

ATA Inc.

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.